CGCatherine Godinot

Catherine Godinot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Catherine Godinot has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Eric Hervouet

    Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, F-25000 Besançon, France

    2 shared publications
  • Hélène Simonnet

    Centre de Génétique Moléculaire et Cellulaire, UMR 5534, Centre National de la Recherche Scientifique, Claude Bernard University of Lyon 1, 43 Boulevard du onze novembre, 69622 Villeurbanne, Cedex, France 7 Present address: UMR 5201, Centre National de la Recherche Scientifique, Université Claude Bernard Lyon 1, F-69373 Lyon, France

    2 shared publications
  • Agnès Rötig

    Université Paris Cité, Institut Imagine, Genetics of Mitochondrial Diseases, INSERM UMR, 1163 Paris, France

    1 shared publication
  • Alena Cízková

    Institute of Physiology, Academy of Sciences of the Czech Republic, Videnska 1083, 142 20 Praha, Czech Republic 3 Institute of Inherited Metabolic Disorders, Faculty of Medicine, Charles University, Ke Karlovu 2, Prague 12808, Czech Republic

    1 shared publication
  • Alena Vojtísková

    Institute of Physiology, Academy of Sciences of the Czech Republic, Videnska 1083, 142 20 Praha, Czech Republic

    1 shared publication
  • Benedicte Mousson de Camaret

    Laboratoire de Biochimie Pédiatrique, Hôpital Debrousse, 69322 Lyon, France

    1 shared publication

Latest Publications

  • Open Access

    HIF and reactive oxygen species regulate oxidative phosphorylation in cancer

    by Eric Hervouet, Alena Cízková, Jocelyne Demont, Alena Vojtísková, Petr Pecina, Nicole L.W. Franssen-Van Hal, Jaap Keijer, Hélène Simonnet, Robert Ivánek, Stanislav Kmoch, et al.

    A decrease in oxidative phosphorylation (OXPHOS) is characteristic of many cancer types and, in particular, of clear cell renal carcinoma (CCRC) deficient in von Hippel–Lindau ( vhl ) gene. In the absence of functional pVHL, hypoxia-inducible factor (HIF) 1-α and HIF2-α subunits are stabilized, which induces the transcription of many genes including those involved in glycolysis and reactive oxygen species (ROS) metabolism. Transfection of these cells with vhl is known to restore HIF-α subunit degradation and to reduce glycolytic genes transcription. We show that such transfection with vhl of 786-0 CCRC (which are devoid of HIF1-α) also increased the content of respiratory chain subunits. However, the levels of most transcripts encoding OXPHOS subunits were not modified. Inhibition of HIF2-α synthesis by RNA interference in pVHL-deficient 786-0 CCRC also restored respiratory chain subunit content and clearly demonstrated a key role of HIF in OXPHOS regulation. In agreement with these observations, stabilization of HIF-α subunit by CoCl 2 decreased respiratory chain subunit levels in CCRC cells expressing pVHL. In addition, HIF stimulated ROS production and mitochondrial manganese superoxide dismutase content. OXPHOS subunit content was also decreased by added H 2 O 2. Interestingly, desferrioxamine (DFO) that also stabilized HIF did not decrease respiratory chain subunit level. While CoCl 2 significantly stimulates ROS production, DFO is known to prevent hydroxyl radical production by inhibiting Fenton reactions. This indicates that the HIF-induced decrease in OXPHOS is at least in part mediated by hydroxyl radical production.


  • Open Access

    New evidence of a mitochondrial genetic background paradox: Impact of the J haplogroup on the A3243G mutation

    by Denis Pierron, Christophe Rocher, Patricia Amati-Bonneau, Pascal Reynier, Marie-Laure Martin-Négrier, Stéphane Allouche, Cécile Batandier, Benedicte Mousson de Camaret, Catherine Godinot, Agnes Rotig, et al.

    Background: The A3243G mutation in the tRNALeu gene (UUR), is one of the most common pathogenic mitochondrial DNA (mtDNA) mutations in France, and is associated with highly variable and heterogeneous disease phenotypes. To define the relationships between the A3243G mutation and mtDNA backgrounds, we determined the haplogroup affiliation of 142 unrelated French patients – diagnosed as carriers of the A3243G mutation – by control-region sequencing and RFLP survey of their mtDNAs. Results: The analysis revealed 111 different haplotypes encompassing all European haplogroups, indicating that the 3243 site might be a mutational hot spot. However, contrary to previous findings, we observed a statistically significant underepresentation of the A3243G mutation on haplogroup J in patients (p = 0.01, OR = 0.26, C.I. 95%: 0.08–0.83), suggesting that might be due to a strong negative selection at the embryo or germ line stages. Conclusion: Thus, our study supports the existence of mutational hotspot on mtDNA and a "haplogroup J paradox," a haplogroup that may increase the expression of mtDNA pathogenic mutations, but also be beneficial in certain environmental contexts.


  • Actuality of Warburg’s views in our understanding of renal cancer metabolism

    by Catherine Godinot, Elodie de Laplanche, Eric Hervouet, Hélène Simonnet

    More than 50 years ago, Warburg proposed that the shift in glucose metabolism from oxidative phosphorylation (OXPHOS) to glycolysis occurring in spite of an adequate oxygen supply was at the root of cancer. This hypothesis often disregarded over the following years has recently stirred up much interest due to progress made in cancer genetics and proteomics. Studies related to renal cancers have been particularly informative to understand how abnormal use of glucose and decrease in OXPHOS are linked to cell proliferation in tumors. Indeed, in aggressive tumors such as clear cell renal carcinoma, the von Hippel–Lindau factor invalidation stabilizes the hypoxia-inducible factor (HIF) in the presence of oxygen. HIF stimulating glycolytic gene expression increases the glycolytic flux. Deficiencies in genes involved in oxidative phosphorylation that can explain the down-regulation of OXPHOS components also begin to be identified. These findings are important in the search for novel therapeutic approaches to cancer treatment.